ARISTOTLE
The total number of patients randomized in Aristotle
18,201
What type of trial is the Athens study
Retrospective, Observational, Real-World Database Analysis
The number of patients in each arm of the Eliquis vs Xarelto cohort in the Aristophanes Obesity Subgroup Analysis
20,431
Amplify-EXT was published in this journal
New England Journal of Medicine
Jin et al was published in this journal
Thrombosis Research
The primary efficacy endpoint of Aristotle
To determine whether Eliquis was non inferior to Warfarin in reducing the risk of stroke or systemic embolism
How many patients were included in the Athens analysis
34,638
The RRR for Eliquis in the incidence of major bleeding in patients with obesity vs Xarelto
48%
percentage of patients enrolled in Amplify who had an unprovoked DVT or PE at baseline.
90%
What were the 3 Primary Outcomes in Jin
Recurrent VTE
Intracranial Hemorrhage
Non-Intracranial Hemorrhage
The percentage of patients in Aristotle with a Chads score of 3 or greater
30%
Athens was published in this journal
Journal of Clinical Medicine
The Aristophanes subgroup analysis for obesity was published in this journal
Journal of Clinical Medicine
In Amplify-EXT, Patients in the Eliquis arm were treated with this dose and for this length of time
2.5mg twice daily for 12 months
What was the RRR for Eliquis vs Xarelto for Recurrent VTE
20%
The percentage RRR for Eliquis vs Warfarin in major bleeding
31%
Which organization(s) funded the research for the Athens Study
Bristol Myers Squibb and Pfizer
Eliquis had an equal incidence of stroke/se in patients with morbid obesity vs this OAC
Xarelto
In Amplify-EXT, Eliquis was similar to placebo for this endpoint
Major bleeding
Which product showed superiority for Intracranial Hemorrhage, Eliquis or Xarelto
Neither. The confidence interval crossed the line of no effect, therefore the outcome for ICH must be considered similar in effect.
Eliquis increases the risk of this
bleeding and can cause serious, potentially fatal bleeding
The assessed outcomes of stroke/SE and incidence of major bleeding also required this as an inclusion criteria.
Hospitalization
The RRR for Eliquis in the incidence of major bleeding in patients with morbid obesity vs Xarelto
53%
Amplify-EXT primary efficacy endpoint
Recurrent VTE or all-cause death
What was the RRR for Eliquis vs Xarelto for Non-Intracranial Hemorrhage
44%
Eliquis had more bleeding in this component of major bleeding
intraocular
What was the propensity score matching ratio in the Athens study
1:5
In the Aristophanes subgroup analysis for Obesity, Eliquis showed superiority in major bleeding vs these OAC's.
None! Retrospective observational analyses are not intended for direct comparison and are only designed to evaluate associations among variables.
There are no results from DOAC vs DOAC head-to-head clinical trials.
In Amplify the RRR for Eliquis vs Enoxaparin/Warfarin in major bleeding events was what percentage?
69%
Patients with these types of insurance were evaluated in the Jin study
Commercially insured and Medicare Advantage Plans